Skip To Main Content

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

Autoimmune Type 1 Diabetes

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.1-4 

The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2

A Paradigm Shift in Early Detection of Autoimmune Type 1 Diabetes

Autoimmune Type 1 diabetes (T1D) is undergoing a fundamental transformation in how the medical community approaches diagnosis and care.

Efluelda® - Vaccin antigrippal saisonnier à haute dose

Airway remodeling in asthma: Why targeting IL-4 and IL-13 matters

Les maladies du voyageur - Fièvre Jaune

Les maladies du voyageur - La rage

Les maladies du voyageur

Les maladies du voyageur - Hépatite A

Les maladies du voyageur - Fièvre typhoïde

Beyfortus® ▼(nirsevimab): effectiveness and public health impact in the real world

Gaucher disease in children

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient activity of the enzyme acid β glucosidase.

DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP

The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3